Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lois Shepherd

Showing results (31-40 of 100) with videos related to

Pageof 10
Sort By:
Annals of Internal Medicine|November 3, 2015
Informed Consent for Research on Medical PracticesLois Shepherd, Ruth Macklin, Nancy M P King, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|October 6, 2010
Ringer's lactate is compatible with saline-adenine-glucose-mannitol preserved packed red blood cells for rapid transfusionBrendan Levac, Joel L Parlow, Janet van Vlymen, et al.
NPJ Breast Cancer|March 11, 2025
Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancerMaj-Britt Jensen, Torsten O Nielsen, John Bartlett, et al.
Breast Cancer Research and Treatment|October 24, 2012
Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-studyKishor M Wasan, Paul E Goss, P Haydn Pritchard, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 20, 2002
Ethics and industry-sponsored researchJoseph L Pater, Wendy Parulekar, Christopher O'Callagham, et al.
Transfusion|May 7, 2019
Can we transfuse wisely in patients undergoing chemotherapy for acute leukemia or autologous stem cell transplantation?Michelle C Lamarche, Danielle E Hammond, Wilma M Hopman, et al.
Plos One|December 25, 2013
RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trialDana Keilty, Marguerite Buchanan, Katerina Ntapolias, et al.
Leukemia & Lymphoma|July 10, 2024
Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trialAbi Vijenthira, Xinzhi Li, Michael Crump, et al.
European Journal of Cancer (Oxford, England : 1990)|April 14, 2021
Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17RJosee-Lyne Ethier, Geoffrey M Anderson, Peter C Austin, et al.
Journal of the National Cancer Institute|February 14, 2008
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancerJudith-Anne W Chapman, Daniel Meng, Lois Shepherd, et al.
Pageof 10

Showing results (31-40 of 100) with videos related to

Sort By:
Pageof 10
Annals of Internal Medicine|November 3, 2015
Informed Consent for Research on Medical PracticesLois Shepherd, Ruth Macklin, Nancy M P King, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|October 6, 2010
Ringer's lactate is compatible with saline-adenine-glucose-mannitol preserved packed red blood cells for rapid transfusionBrendan Levac, Joel L Parlow, Janet van Vlymen, et al.
NPJ Breast Cancer|March 11, 2025
Prosigna Risk of Recurrence score and intrinsic subtypes are associated with adjuvant anthracycline chemotherapy benefit in high-risk breast cancerMaj-Britt Jensen, Torsten O Nielsen, John Bartlett, et al.
Breast Cancer Research and Treatment|October 24, 2012
Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an NCIC CTG MA.17 sub-studyKishor M Wasan, Paul E Goss, P Haydn Pritchard, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 20, 2002
Ethics and industry-sponsored researchJoseph L Pater, Wendy Parulekar, Christopher O'Callagham, et al.
Transfusion|May 7, 2019
Can we transfuse wisely in patients undergoing chemotherapy for acute leukemia or autologous stem cell transplantation?Michelle C Lamarche, Danielle E Hammond, Wilma M Hopman, et al.
Plos One|December 25, 2013
RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trialDana Keilty, Marguerite Buchanan, Katerina Ntapolias, et al.
Leukemia & Lymphoma|July 10, 2024
Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trialAbi Vijenthira, Xinzhi Li, Michael Crump, et al.
European Journal of Cancer (Oxford, England : 1990)|April 14, 2021
Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17RJosee-Lyne Ethier, Geoffrey M Anderson, Peter C Austin, et al.
Journal of the National Cancer Institute|February 14, 2008
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancerJudith-Anne W Chapman, Daniel Meng, Lois Shepherd, et al.
Pageof 10